Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia
暂无分享,去创建一个
P. Ouillette | S. Malek | A. Melnick | K. Shedden | R. Shaknovich | Jinghui Li | Yifeng Li
[1] Y. Pekarsky,et al. Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies. , 2012, Blood.
[2] E. Giné,et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.
[3] K. Kinzler,et al. Sequence analysis of 515 kinase genes in chronic lymphocytic leukemia , 2011, Leukemia.
[4] A. Sivachenko,et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.
[5] M. Kaminski,et al. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. , 2011, Blood.
[6] N. Chiorazzi,et al. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. , 2011, Blood.
[7] M. Kaminski,et al. A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia , 2011, Clinical Cancer Research.
[8] Y. Pekarsky,et al. Tcl 1 interacts with Atm and enhances NF-kB activation in hematological malignancies , 2011 .
[9] L. Ding,et al. Aggressive Chronic Lymphocytic Leukemia with Elevated Genomic Complexity Is Associated with Multiple Gene Defects in the Response to DNA Double-Strand Breaks , 2010, Clinical Cancer Research.
[10] A. Melnick,et al. HELP (HpaII tiny fragment enrichment by ligation-mediated PCR) assay for DNA methylation profiling of primary normal and malignant B lymphocytes. , 2010, Methods in molecular biology.
[11] M. Hallek,et al. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. , 2009, Blood.
[12] T. Shanafelt,et al. Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Quan Chen,et al. An analytical pipeline for genomic representations used for cytosine methylation studies , 2008, Bioinform..
[14] R. Siebert,et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] T. Stankovic,et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. , 2005, Blood.
[16] M. Kastan,et al. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation , 2003, Nature.
[17] R. Houlston,et al. ATM mutations are rare in familial chronic lymphocytic leukemia , 2002 .
[18] A Benner,et al. Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.
[19] H. Döhner,et al. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. , 1999, Blood.
[20] T. Stankovic,et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia , 1999, The Lancet.
[21] C. Croce,et al. ATM mutations in B-cell chronic lymphocytic leukemia. , 1999, Cancer research.
[22] H. Kantarjian,et al. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. , 1998, Cancer research.
[23] C. Fegan,et al. Karyotypic evolution in CLL: identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. , 1995, Leukemia.
[24] S. Knuutila,et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. , 1990, The New England journal of medicine.